{"id":"intra-nasal-ketamine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ketamine antagonizes N-methyl-D-aspartate (NMDA) receptors, which are ionotropic glutamate receptors involved in excitatory neurotransmission. By blocking these receptors, ketamine disrupts glutamatergic signaling and produces rapid-onset dissociative, analgesic, and in some cases antidepressant effects. The intranasal formulation allows direct delivery to the nasal mucosa for systemic absorption, potentially offering faster onset and non-invasive administration compared to intravenous routes.","oneSentence":"Intranasal ketamine is a non-competitive NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce dissociative and analgesic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:31.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"},{"name":"Acute pain management"},{"name":"Anesthesia induction"}]},"trialDetails":[{"nctId":"NCT07380763","phase":"NA","title":"Comparison of Peri-intubation Oxygenation Values and Complications in Patients Intubated With the Delayed Versus Rapid Sequence Intubation Protocols","status":"RECRUITING","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2025-10-29","conditions":"Delayed Sequence Intubation, Rapid Sequence Induction and Intubation, Intubation","enrollment":140},{"nctId":"NCT02644629","phase":"PHASE4","title":"Intra-nasal vs. Intra-venous Ketamine Administration","status":"COMPLETED","sponsor":"Shalvata Mental Health Center","startDate":"2016-04","conditions":"Major Depressive Disorder","enrollment":45},{"nctId":"NCT03053947","phase":"PHASE2","title":"Pain Free Laceration Repairs Using Intra-nasal Ketamine","status":"COMPLETED","sponsor":"Evelyne D.Trottier","startDate":"2017-02-16","conditions":"Laceration","enrollment":42},{"nctId":"NCT02033434","phase":"PHASE1","title":"Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2014-03-01","conditions":"Pain, Traumatic Limb Injury","enrollment":30},{"nctId":"NCT03233035","phase":"PHASE2","title":"Low Dose Ketamine Intra Nasal Traumatology","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2018-01-01","conditions":"Trauma","enrollment":1102},{"nctId":"NCT03511833","phase":"PHASE3","title":"Comparison of Treatment by IN Ketamine to IV Morphine in Acute Pain","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2019-12","conditions":"Acute Traumatic Pain","enrollment":120},{"nctId":"NCT02753114","phase":"PHASE4","title":"Prehospital Analgesia With Intra-Nasal Ketamine","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2017-11-06","conditions":"Pain, Acute Pain","enrollment":120},{"nctId":"NCT01686009","phase":"PHASE4","title":"Intra-nasal Ketamine for Analgesia in the Emergency Department","status":"COMPLETED","sponsor":"Lions Gate Hospital","startDate":"2012-10","conditions":"Pain","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intra-nasal ketamine","genericName":"Intra-nasal ketamine","companyName":"Lions Gate Hospital","companyId":"lions-gate-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intranasal ketamine is a non-competitive NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce dissociative and analgesic effects. Used for Treatment-resistant depression, Acute pain management, Anesthesia induction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}